Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study

2010 ◽  
Vol 25 (9) ◽  
pp. 2846-2850 ◽  
Author(s):  
F. Locatelli ◽  
P. Aljama ◽  
B. Canaud ◽  
A. Covic ◽  
A. De Francisco ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Position Statement ◽  
Erythropoiesis Stimulating Agents ◽  
Target Haemoglobin

scholarly journals Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

2018 ◽  
Vol Volume 10 ◽  
pp. 1371-1380 ◽  
Author(s):  
Erzsébet Horváth-Puhó ◽  
Marit M Suttorp ◽  
Henrik Frederiksen ◽  
Tiny Hoekstra ◽  
Olaf M Dekkers ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Myelodysplastic Syndrome ◽  
Cardiovascular Events ◽  
Erythropoiesis Stimulating Agents

scholarly journals Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

2017 ◽  
Vol 1 (19) ◽  
pp. 1538-1545 ◽  
Author(s):  
Zachary Gowanlock ◽  
Swetha Sriram ◽  
Alison Martin ◽  
Anargyros Xenocostas ◽  
Alejandro Lazo-Langner
Keyword(s):  
Elderly Patients ◽  
Cardiovascular Events ◽  
Cardiovascular Outcomes ◽  
Unknown Etiology ◽  
Type Ii ◽  
Type Ii Error ◽  
Erythropoiesis Stimulating Agents ◽  
Key Points

Key Points ESAs can treat anemia of unknown etiology, and responses may be similar to those in CKD. No statistically significant increase in cardiovascular events in those receiving ESAs was detected, but a type II error cannot be excluded.

Sign in / Sign up

Export Citation Format

Share Document